{"a": [["Standards of medical care for patients with diabetes mellitus", "2003"], ["Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation", "1998"], ["Publication bias in obesity treatment trials?", "1996"], ["Association of funding and conclusions in randomized drug trials; a reflection of treatment effect or adverse events?", "2003"], ["Obesity and disease management: effects of weight loss on comorbid conditions", "2001"], ["Does blinding of readers affect the results of meta\u2010analyses? Results of a randomized trial", "1997"], ["Medical evaluation of the obese patient with cardiovascular disease", "1987"], ["Current and potential drugs for treatment of obesity", "1999"], ["Promoting weight loss in type II diabetes", "1996"], ["Improving long\u2010term weight loss: pushing the limits of treatment", "1987"], ["Cochrane Reviewers' Handbook 4.2.0 (updated March 2003)", "2003"], ["The combination of estimates from different experiments", "1954"], ["Behavior therapy and pharmacotherapy for obesity", "1981"], ["Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance", "1979"], ["The effect of intensive treatment of diabetes on the development and progression of long\u2010term complications in insulin\u2010dependent diabetes mellitus", "1993"], ["Meta\u2010analysis in clinical trials", "1954"], ["Physican interpretations and textbook definitions of blinding terminology in randomized controlled trials", "2002"], ["Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin", "2002"], ["Systematic reviews and lifelong diseases", "2002"], ["Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus", "2002"], ["Prevalence and trends in obesity among U.S. adults, 1999\u20102000", "2002"], ["Long\u2010term weight loss: the effect of pharmacologic agents", "1994"], ["Obesity medications and the treatment of type 2 diabetes", "1999"], ["The impact of pharmacotherapy on weight management in type 2 diabetes", "1999"], ["Advisory: Health Canada investigates safety of MERIDIA (sibutramine). Health Canada Online 3\u201027\u20102002", "2002"], ["Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high\u2010normal blood pressure", "1997"], ["Guidelines for meta\u2010analyses evaluating diagnostic tests", "1994"], ["Assessment the quality of RCTs: why, what, how, and by whom?", "1998"], ["Selective attrition causes overestimates of treatment effects in studies of weight loss", "1987"], ["Global Burden of diabetes, 1995\u20102025: prevalence, numerical estimates, and projections", "1998"], ["Long\u2010term follow\u2010up of behavioral treatment for obesity: patterns of weight regain in men and women", "1989"], ["By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?", "1994"], ["Cardiorespiratory fitness, body composition, and all\u2010cause and cardiovascular disease mortality in men", "1999"], ["The prevention and treatment of obesity. Application to type 2 diabetes", "1997"], ["Diabetes trends in the U.S.: 1990\u20101998", "2000"], ["The continuing epidemics of obesity and diabetes in the United States", "2001"], ["Long\u2010term pharmacotherapy in the management of obesity", "1996"], ["Clinical guidelines on the identification, evaluation, and treatment of overwieght and obesity in adults: the evidence report", "1998"], ["Health implications of obesity: National Institutes of Health Consensus Development Conference Statement", "1985"], ["Systematic review of the effectiveness of interventions used in the management of obesity", "1998"], ["Long\u2010term pharmacotherapy for obesity and overweight Long\u2010term pharmacotherapy for obesity and overweight", "2004"], ["Combining behavioral and pharmacological treatments for obesity", "2002"], ["Medical hazards of obesity", "1993"], ["Weight loss and mortality in type 2 diabetes", "2000"], ["Antiobesity pharmacotherapy in the management of type 2 diabetes", "2000"], ["New antiobesity agents in type 2 diabetes: Overview of clinical trials with sibutramine and orlistat", "2002"], ["Investigating and dealing with publication and other biases", "2001"], ["Misleading funnel plot for detection of bias in meta\u2010analysis", "2000"], ["Introducing the Guide to Community Preventive Services: methods, first recommendations and expert commentary", "2000"], ["Publication bias in meta\u2010analysis: its causes and consequences", "2000"], ["Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance", "2001"], ["Cardiac valvulopathy associated with exposure to fenfluramine and dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations", "1997"], ["National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2000", "2002"], ["Diabetes: disabling, deadly and on the rise, 2002", "2002"], ["Intensive blood\u2010glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", "1998"], ["Effects of weight loss on morbidity and mortality", "2002"], ["Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five\u2010year perspective", "1989"], ["Behavioral treatment of obesity", "2000"], ["Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial", "2001"], ["The global strategy on diet, physical activity and health", "2002"], ["Obesity and overweight", "2003"], ["World Health Organization Technical Report", "1980"], ["World Health Organization Technical Report.", "1985"], ["Intentional weight loss and mortality among overweight individuals with diabetes", "2000"], ["Behavior change, weight loss, and physiological improvements in type II diabetic patients", "1985"], ["Long\u2010term effects of modest weight loss in type II diabetic patients", "1987"], ["Effects of a very\u2010low\u2010calorie diet on long\u2010term glycemic control in obese type 2 diabetic subjects", "1991"], ["Behavioral treatment of severe obesity", "1992"], ["Weight loss in the management of type 2 diabetes", "2000"], ["Strategies for changing eating and exercise behavior", "2001"], ["Letter from Public Citizen to Tommy Thompson, Secretary DHHS", "2002"], ["Obesity", "2002"], ["The prevention and treatment of obesity", "1997"]], "ex": [["Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity", "1997"], ["Long\u2010term maintenance of weight loss after a very\u2010low\u2010calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine", "1999"], ["Enhanced thermogenic responsiveness during chronic ephedrine treatment in man", "1985"], ["The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy\u2010restricted diet: A double blind trial", "1992"], ["Reductil (sibutramine hydrochloride) effect in treating obese patients", "2002"], ["Addition of orlistat to long term phentermine treatment for obesity", "2000"], ["A double\u2010blind randomized placebo\u2010controlled trial of sibutramine", "1996"], ["Sibutramine produces dose\u2010related weight loss", "1999"], ["Long\u2010term effects of fluoxetine on glycemic control in obese patients with non\u2010insulin\u2010dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity", "1995"], ["Randomised trial of the effect of orlistat on body weight and CVD risk profile in overweight and obese patients with co\u2010morbidities", "2001"], ["Long\u2010term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case\u2010series", "2001"], ["Evaluation of Sanorex\u2010a new appetitie suppressant", "1973"], ["Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity", "1993"], ["Fluoxetine's effect on weight loss in obese subjects", "1991"], ["Weight control and risk factor reduction in obese subjects treated for 2 years with Orlistat: a randomized controlled trial", "1999"], ["Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke", "1999"], ["Orlistat (Ro 18\u20100647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study", "1995"], ["Phenmetrazine hydrochloride and methylcellulose in the treatment of 'refractory' obesity", "1960"], ["Ephedrine: new treatment for diabetic neuropathic edema", "1983"], ["Use of teronak for the treatment of obesity with and without diabetes mellitus", "1979"], ["Short\u2010term and long\u2010term clinical evaluation of a non\u2010amphetaminic anorexiant (mazindol) in the treatment of obesity", "1976"], ["A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity", "2000"], ["Sibutramine reduces glucose intolerance in centrally obese hypertensive patients", "2001"], ["Fluoxetine versus sertraline and paroxetine in major depression: long\u2010term changes in weight", "1999"], ["Comparison of fluoxetine and placebo in the treatment of obesity", "1995"], ["One\u2010year treatment of obesity: a randomized, double\u2010blind, placebo\u2010controlled multicentre study of orlistat, a gastrointestinal lipase inhibitor", "2000"], ["Cimetidine: Weight loss", "2001"], ["Effects of sibutramine in non\u2010dieting obese women", "2002"], ["Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity", "2002"], ["Fluoxitine: a randomized clinical trial in the maintenance of weight loss", "1993"], ["Fluoxetine: a randomized clinical trial in the treatment of obesity", "1994"], ["Double\u2010blind, randomized, placebo\u2010controlled clinical trials with non\u2010prescription medications for the treatment of obesity", "1999"], ["Weight reduction with phenmetrazine and chlorphentermine a double\u2010blind study", "1967"], ["Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids", "2000"], ["Effect of orlistat on post\u2010prandial glucose levels in overweight or obese patients with type 2 diabetes", "2002"], ["A comparison of sibutramine and dexfenfluramine in the treatment of obesity", "1998"], ["Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity, results from the European multi\u2010centre STORM trial", "2001"], ["Initial studies in humans with the novel gastointestinal lipase inhibitor Ro 18\u20100647", "1992"], ["Orlistat in the long\u2010term treatment of obesity in primary care settings", "2000"], ["A comparison of the effects on central 5\u2010HT function of sibutramine hydrochloride and other weight\u2010modifying agents", "1998"], ["Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes mellitus", "1999"], ["Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults", "2000"], ["Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1\u2010y study", "1999"], ["Treatment of patients with non\u2010insulin\u2010dependent diabetes mellitus: diabetic control and insulin secretion and action after different treatment modalities", "1987"], ["Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan", "1992"], ["Clinical studies with mazindol", "1995"], ["Effect of Orlistat on glycemic control in patients on or near maximal doses of oral anti\u2010diabetic (OAD) medications", "2002"], ["A one year trial to assess the value of orlistat in the management of obesity", "1997"], ["Effect of sibutramine on weight maintenance after weight loss: a randomised trial", "2000"], ["Long term weight loss with sibutramine", "1995"], ["A double\u2010blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity", "1974"], ["Therapeutic comparison of metformin and fluoxetine alone and in combination in obese subjects with impaired glucose tolerance", "1999"], ["Use of metformin and fluoxetine combination in obese subjects with glucose intolerance", "1999"], ["Fluoxetine for depression in diabetes: a randomized double\u2010blind placebo\u2010controlled trial", "2000"], ["Cost\u2010effectiveness of treatment of overweight and obese diabetic patients with Orlistat", "2002"], ["Fluoxetine improves insulin sensitivity in obese patients with non\u2010insulin\u2010dependent diabetes mellitus independently of weight loss", "1997"], ["Ephedrine as an anorectic: The story of the &quot;Elsinore pill&quot;", "1981"], ["A double\u2010blind, placebo\u2010controlled trial of fluoxetine plus behavior modification in the treatment of obese binge\u2010eaters and non\u2010binge\u2010eaters", "1990"], ["Metabolic changes following sibutramine\u2010assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity", "2001"], ["Efficacy and safety of sibutramine in obese white and African American patients with hypertension \u2010 A 1\u2010year, double\u2010blind, placebo\u2010controlled, multicenter trial", "2000"], ["Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics", "1992"], ["Changes in weight during a 1\u2010year trial of fluoxetine", "1999"], ["Effect of orlistat in overweight and obese type 2 diabetes patients treated with metformin", "2001"], ["Effect of orlistat on the need for concomitant anti\u2010diabetic medication in overweight and obese patients with type 2 diabetes", "2002"], ["Does ephedrine promote weight loss in low\u2010energy\u2010adapted obese women?", "1987"], ["The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial", "1996"], ["Bromocriptine: a novel approach to the treatment of type 2 diabetes", "2000"], ["Cimetidine suspension as adjuvant to energy restricted diet in treating obesity", "1993"], ["Weight loss with sibutramine in obese patients with type 2 diabetes: a double\u2010blind, placebo\u2010controlled study", "1999"], ["Sibutramine\u2010induced weight loss improves lipid profile in obese type 2 diabetics: Results of 3 placebo\u2010controlled, randomized trials", "2000"], ["Weight loss on sibutramine treatment for 12 months improves lipid profile in obese type 2 diabetic patients", "2000"], ["Sibutramine reduces food intake in non\u2010dieting women with obesity", "1998"], ["Minor long\u2010term changes in weight have beneficial effects on insulin sensitivity and beta\u2010cell function in obese subjects", "2002"], ["Effect of moderate weight loss on health\u2010related quality of life: An analysis of combined data from 4 randomized trials of sibutramine vs placebo", "2001"], ["Yohimbine does not affect fat distribution in men", "1991"], ["Effects of sibutramine on resting metabolic rate and weight loss in overweight women", "1998"], ["Diethylpropion hydrochloride (Tenuate Dospan) in combination with hypotensive agents in the treatment of obesity associated with hypertension", "1974"], ["Effect of orlistat on weight loss and glycemic control in overeight Chinese patients with type 2 diabetes", "2001"], ["Hyperinsulinemia secondary to chronic administration of mazindol and d\u2010amphetamine", "1971"], ["Randomised placebo\u2010controlled trail of orlistat for weight losss and prevention of weight regain in obese patients; European Multicentre Orlistat Study Group", "1998"], ["A comparative trial of different regimens of fenfluramine and phentermine in obesity", "1973"], ["Effect of cimetidine suspension on appetite and weight in overweight subjects", "1993"], ["Acute effect of orlistat on post\u2010prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus", "2002"], ["Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin", "1998"], ["Continuous subcutaneous infusion of glucagon\u2010like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients", "1999"], ["The reduction of overweight and the improvement of metabolic parameters with the lipase inhibitor orlistat: Preliminary results [German]", "1998"], ["Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience", "2001"], ["The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans", "1993"], ["Efficacy and tolerability of orlistat in the treatment of obesity \u2010 A 6\u2010month dose\u2010ranging study", "1998"], ["Sibutramine trial of obesity reduction and maintenance. Effects on risk factors", "1998"], ["Fluoxetine increases insulin action in obese type\u2010II (non\u2010insulin\u2010dependent) diabetic\u2010patients", "1992"], ["Controlled comparative investigation of mazindol, D\u2010amphetamine, and placebo", "1974"], ["Sertraline and relapse prevention training following treatment by very\u2010low\u2010calorie diet: A controlled clinical trial", "1995"], ["Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach", "1997"], ["Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial", "2001"], ["A multicentre atudy comparing mazindol and placebo in obese patients", "1977"], ["Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients", "2000"], ["Obesity with orlistat (Xenical) helps to prevent deterioration in glucose tolerance", "1998"], ["Orlistat\u2010induced weight loss improves insulin resistance in obese patients", "1999"], ["Early response to orlistat treatment predicts long\u2010term success in overweight and obese patients with co\u2010morbidities", "2001"], ["Weight reduction in osteoarthritis using phentermine", "1981"], ["A clinical evaluation of Tenuate\u2010 a new anti\u2010appetite compound", "1960"], ["Long\u2010term weight losss with sibutramine: a randomized, controlled trial", "2001"], ["A double\u2010blind controlled trial of a new anorectic agent AN448", "1975"], ["Usefulness of mazinol in combined diet therapy consisting of low\u2010calorie diet and optifast in severely obese women", "1994"], ["Treatment with orlistat reduces cardiovascular risk in obese patients", "1998"], ["Therapy of obesity with &quot;Redukal&quot;", "1971"]], "in": [["Orlistat in Obese Patients with Type 2 Diabetes: A Retrospective Assessment of Weight Loss and Metabolic Effects", "2004"], ["Absence of cardiac valve dysfunction in obese patients treated with sibutramine", "1999"], ["Double\u2010blind clinical evaluation of mazindol (42\u2010548) in obese diabetics", "1975"], ["Orlistat in hypertensive overweight/obese patients: Results of a randomized clinical trial", "2003"], ["Effect of orlistat on glycemic control and body weight in overweight or obese South African patients with type 2 diabetes", "2002"], ["The efficacy and safety of Mazindol in patients with diabetes mellitus", "1974"], ["Weight reduction in obese diabetics: a double\u2010blind study of diethylpropionate", "1979"], ["Weight control in obese diabetics. A comparetive trial of Filon and Phenmetrazine", "1966"], ["A controlled trial of phentermine in obese diabetic patients", "1977"], ["Fluoxetine has potential in obese NIDDM \u2010 Multicenter Canadian trial", "1989"], ["A study of fluoxetine in obese elderly patients with type 2 diabetes", "1995"], ["Noramphetamine, anorectic medication for obese diabetic patients: controlled and open investigations of mazindol", "1974"], ["Usefulness of fluoxitine in obese non\u2010insulin\u2010dependent diabetics: a multicenter study", "1996"], ["Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes", "2001"], ["Effect of orlistat on insulin resistance, cardiovascular risk factors and serum leptin levels in obese type 2 diabetic patients", "2001"], ["Mazindol in the treatment of obese diabetic patients", "1976"], ["Mazindol in the treatment of obesity in diabetics", "1976"], ["Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes; a randomised, double\u2010blind, placebo\u2010controlled study", "2000"], ["Weight loss with sibutramine improves glcaemic control and other metabolic parameters in ovese patients with type 2 diabetes mellitus", "2000"], ["The effect of a low calorie diet and an anorectic agent on body weight and on serum insulin, cholesterol, and triglyceride levels obese diabetics", "1972"], ["Effects of diet and an anorectic drug (phentermine resin) in obese diabetics", "1977"], ["Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control", "2001"], ["Fluoxetine treatment of obese patients with noninsulin dependent diabetes\u2010mellitus", "1991"], ["Fluoxetine therapy in obese patients with noninsulin\u2010dependent diabetes mellitus", "1995"], ["A randomized double\u2010blind clinical trial of fluoxetine in obese diabetics", "1992"], ["Sibutramine in the treatment of overweight non\u2010insulin\u2010dependent diabetics", "1995"], ["Differential weight loss in orlistat treated obese and overweight patients with various comorbidities", "2001"], ["Latin\u2010American multicentric study with orlistat in overweight or obese patients with type 2 diabetes", "2001"], ["Orlistat promotes weight loss and improves glycaemic control in overweight patients with type 2 diabetes", "2001"], ["Orlistat promotes glucemia control and other cardiovascular risk factors lowering in obese patients with type 2 diabetes. Randomised clinical trial", "2000"], ["Use of diethylpropion in obese diabetic persons", "1962"], ["Orlistat enhances weight loss in obese patients with diabetes", "1997"], ["Effects of orlistat in obese metformin\u2010treated patients with type 2 diabetes: attainment of treatment goals", "2001"], ["Health\u2010related quality of life in a randomised placebo\u2010controlled trial of sibutramine in obese patients with type II diabetes", "2004"], ["A one\u2010year study of weight loss and glycemic control in type 2 diabetics following orlistat treatment", "1997"], ["Effect of orlistat in overweight patients with diabetes receiving insulin therapy", "2001"], ["Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes", "2004"], ["Eight weeks fluoxitine therapy in obese patients with impaired glucose tolerance", "1990"], ["Fluoxetine therapy in obese diabetic and glucose intolerant patients", "1992"], ["Biochemical markers of patients with type 2 diabetes and orlistat induced weight loss", "2001"], ["The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study", "2000"], ["Weight loss in type 2 diabetics treatd with orlistat", "2001"], ["A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin", "2003"], ["Orlistat reduces visceral fat independent of weight changes in obese diabetics type 2", "2000"], ["Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin", "2002"], ["Experience on the therapeutic use of an anorexic substance in obese diabetes", "1964"], ["Fluoxetine in the treatment of obese type 2 diabetic patients", "1994"], ["The effect of sibutramine on weight loss and glucose metabolism in obese patients with type 2 diabetes mellitus", "1999"], ["One\u2010year outcome of a combination of weight loss therapies for subjects with type 2 diabetes \u2010 A radomized trial", "2003"], ["Weight loss with sibutramine in obese patients with type 2 diabetes: a double\u2010blind, placebo\u2010controlled study", "1999"], ["The effect of an anorectic agent (Mazindol) on control of obese diabetics", "1976"], ["Impact of orlistat\u2010induced weight loss on cardiovascular risk estimate in diabetic and non\u2010diabetic subjects", "2000"], ["Orlistat efficacy on weight loss in overweight or obese patients with type 2 diabetes mellitus", "2001"], ["Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy", "2002"], ["Obesity in diabetes. Some considerations on treatment", "1966"], ["Clinical evaluation of sibutramine in obese type 2 diabetic patients refractory to dietary management", "2001"], ["Double\u2010blind clinical trial of mazindol on weight loss, blood glucose, plasma insulin and serum lipids in overweight diabetic patients", "1978"], ["Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes", "1998"], ["Sibutramine in the treatment of obesity in type 2 diabetic patients. [Bulgarian]", "2003"], ["Effect of orlistat on cardiovascular risk factors and insulin sensitivity in young obese Chinese type 2 diabetic patients", "2001"], ["Effects of Sibutramine", "1994"], ["Orlistat in obese type 2 diabetes mellitus: metabolic effects of a short term treatment", "2000"], ["Orlistat for adjutant treatment of fatty type 2 diabetes mellitus in 32 patients", "2003"], ["Trial of a long\u2010acting preparation of diethylpropion in obese diabetics", "1968"], ["Fluoxetine, efficacy and safety in treatment of obese type\u20102 (non\u2010insulin\u2010dependent) diabetes", "1989"], ["Highly educative programme added upon treatment with orlistat in type 2 diabetic patients", "2002"], ["Growth hormone secretion in obese patients with non\u2010insulin dependent diabetes mellitus: effect of weight reduction and of fluoxetine treatment", "1992"]]}